Accumulation of CD62P during storage of apheresis platelet concentrates and the role of CD62P in transfusion-related acute lung injury

SHAN TONG, HAIBAO WANG, TING ZHANG, LINFENG CHEN and BOWEI LIU

Department of Blood Transfusion, The General Hospital of The People's Liberation Army, Beijing 100085, P.R. China

Received November 8, 2014; Accepted August 25, 2015

DOI: 10.3892/mmr.2015.4347

Abstract. Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-associated morbidity and mortality. Activated platelets have important roles in TRALI and CD62P was identified to be an important indicator of platelet activation. However, the precise roles of CD62P in TRALI have remained elusive. The present study assessed CD62P accumulation during storage of apheresis platelet concentrates (A-Plts) and established a mouse model of TRALI to further investigate the roles of CD62P in TRALI. The results showed that the CD62P concentration in A-Plts was increased with the storage time. Mice were treated with monoclonal major histocompatibility complex (MHC)-1 antibody to induce TRALI. The murine model of TRALI was successfully established as evidenced by pulmonary oedema, accompanied by decreased clearance of bronchoalveolar lavage fluid (BALF), increased pulmonary and systemic inflammation, elevated lung myeloperoxidase (MPO) activity as well as increased pulmonary and systemic coagulation in the TRALI group compared with those in the control group. To further determine the role of CD62P in TRALI, mice were treated with anti-CD62P antibody to knockdown CD62P in vivo. It was found that pulmonary oedema, BALF clearance, pulmonary and systemic inflammation, MPO activity as well as pulmonary and systemic coagulation were decreased in the TRALI + anti-CD62P antibody group compared with those in the TRALI + isotype antibody group. The present study supported the notion that CD62P is involved in mediating TRALI and may provide an important molecular basis for enhancing the clinical safety and effectiveness of platelet transfusion.

Introduction

Transfusion-related acute lung injury (TRALI) is a complex syndrome which is characterized by acute hypoxia and non-cardiogenic pulmonary edema occurring within six hours of blood transfusion and is the leading cause of transfusion-associated morbidity and mortality (1-3). Platelets have been implicated in the triggering of neutrophils, which leads to the damage of the vasculature (4-6). CD62P is a Ca$^{2+}$-dependent receptor stored in the alpha-granules of platelets and Weibel-Palade bodies of endothelial cells (7,8). It translocates to the plasma membrane and is released into the plasma in soluble form during platelet activation (9,10), mediating the interaction of activated endothelial cells or platelets with leukocytes upon inflammatory and thrombogenic challenges (11‑13). A study by Looney et al (14) found that depletion of either neutrophils or platelets had protective effects against lung injury in an immune-mediated mouse model of TRALI. CD62P was identified to be an important indicator of platelet activation (15,16) and activated platelets have been implicated in the occurrence of TRALI (17,18). However, the precise roles of CD62P in the occurrence of TRALI have remained elusive.

The present study assessed CD62P accumulation during storage of apheresis platelet concentrates (A-Plts) and established a murine model of TRALI to further investigate the role of CD62P in TRALI.

Materials and methods

A-Plts collection. The present study was approved by the Ethics Committee of The General Hospital of The People's Liberation Army (Beijing, China). A total of 25 A-Plts samples were collected from healthy volunteers and stored according to standard procedures according to the blood donation law of the People's Republic of China.

Assessment of CD62P. The CD62P concentration in A-Plts was measured using a Human sP-Selectin/CD62P ELISA kit (cat. no. SBBE6; R&D Systems, Inc., Minneapolis, MN, USA), following the manufacturer's instructions.

Establishment of a TRALI model and anti-CD62P antibody treatment. Male BALB/c mice, aged 8-10 weeks and weighing...
250±30g were purchased from Shanghai Slac Laboratory Animal Company (Shanghai, China). A total of 40 were used, which were maintained in individual cages in a room with a controlled temperature (22-24°C) and light cycle (12 h light/dark), free access to food and fresh water. The TRALI model was constructed according to Looney's method (14). The mice were anesthetized with ketamine (80mg/kg; Eurovet Animal Health B.V., Bladel, The Netherlands) and xylazine (12mg/kg; Bayer AG, Leverkusen, Germany) intra-peritoneally (i.p.). Subsequently, the mice were placed in a supine position on a warming blanket and the jugular vein was isolated. A 30-gauge sterile needle was attached to polyethylene tubing and venous blood was aspirated from the jugular vein to verify intravascular placement of the needle. The mice were injected with lipopolysaccharide (0.1mg/kg i.p.) 24 h prior to intravenous injection with 150-250µl (6mg/ml) mouse monoclonal anti-major histocompatibility complex (MHC)-1 immunoglobulin (Ig)G2a, κ [4.5mg/kg; cat. no. HB-79; American Type Culture Collection (ATCC), Manassas, VA, USA], while control mice were injected with phosphate-buffered saline (PBS; 0.1mg/kg i.p.) 24 h prior to injection with isotype-matched mouse monoclonal antibody (mAb) (IgG2a, κ; 4.5mg/kg; cat. no. CRL-1908; ATCC). For CD62P neutralization studies, mice received rat monoclonal anti-CD62P antibody (25µg/mouse; IgG1; cat. no. 553743; BD Biosciences, San Jose, CA, USA) or isotype control antibody 15 min prior to TRALI. The skin was sutured with prolene 5-0 (Johnson & Johnson, Inc., St. Stevens-Woluwe, Belgium). The mice were placed back into their cages following recovery from anaesthesia. The mice were sacrificed 2 h following the establishment of the TRALI model via an i.p. injection of pentobarbital (200mg/kg; Sigma-Aldrich, St. Louis, MO, USA).

Branch alveolar lavage fluid (BALF) and blood collection. The right lung was ligated, the left lung was lavaged with 2ml 0.9% saline through the tracheal cannula for three times and the BALF was retrieved. The BALF was centrifuged for 15 min at 450 x g and the supernatant was stored at -80°C for measurement of protein levels. 2 h following TRALI, blood was collected from the carotid artery and placed in 3.2% sodium citrate-containing tubes (Wenzhou Gande Medical Instrument Co., Ltd., Wenzhou, China). Following centrifugation at 800 x g for 15 min, the plasma was separated and stored at -80°C.

Determination of total protein, cytokines and thrombin-anti-thrombin complex (TATc). The concentration of total protein in the BALF was measured using a Bradford Protein Assay kit (cat. no. 5000001; Bio-Rad Laboratories Inc, Hercules, CA, USA) following the manufacturer's instructions. Briefly, albumin was used to prepare a protein standard curve. Samples were diluted with buffer, then dye reagent was added to each sample and incubated for 5 min. The absorbance at 590 nm was measured using a visible light spectrophotometer (Alpha 1102; LASPEC Inc., Shanghai, China). The concentration of each sample was calculated according to the protein standard curve.

The concentrations of interleukin (IL)-6, macrophage inflammatory protein 2 (MIP-2) and keratinocyte-derived chemokine (KC) in the plasma and the BALF was determined using the following commercial ELISA kits: Mouse IL-6 Quantikine ELISA kit (cat. no. M6000B), Mouse CXCL2/MIP-2 Quantikine ELISA kit (cat. no. MM200) and a Mouse CXCL1/KC Quantikine ELISA kit (cat. no. MKC00B), all obtained from R&D Systems. The detection limit was 1.8, 1.5 and 2 pg/ml, respectively. TATc in the plasma and the BALF was measured using a Mouse thrombin-antithrombin complex TAT ELISA kit (cat.no. MU30254; Bio-Swamp Life Science, Wuhan, China), according to the manufacturer’s instructions.

Myeloperoxidase (MPO) assay. The lung tissues were homogenized in PBS containing 0.1% NP40 in a Dounce glass homogenizer (Thomas Scientific, Swedesboro, NJ, USA) and centrifuged for 10 min at 13,000 x g and 4°C to remove any insoluble material. MPO activity was measured using an MPO Activity Colorimetric Assay kit (cat. no. K744-100; BioVision, Milpitas, CA, USA), according to the manufacturer's instructions.

Statistical analysis. Values are expressed as the mean ± standard deviation. Student's t test was used to assess differences between the two groups. Statistical analysis was performed using SPSS 19.0 statistical software (IBM SPSS, Armonk, NY, USA). P<0.05 was considered to indicate a significant difference between values.

Results

CD62P accumulates in stored A-Plts. CD62P expression in A-Plts with a storage time of 0, 1, 3 and 5 days was detected using a commercial ELISA kit. As shown in Fig. 1, the CD62P concentration in A-Plts was increased with the storage time. CD62P concentrations on days 0 and 1 of storage were not significantly different (P>0.05). However, CD62P concentrations on days 3 and 5 of storage were significantly increased compared with those at days 0 and 1.
CD62P is involved in the formation of pulmonary edema in a murine model of TRALI. As a measure of pulmonary edema, the lung W/D weight ratio of mice was determined following TRALI. As shown in Fig. 2, compared with the control group, a significant increase of the W/D weight ratio was observed in the TRALI group (P<0.01). To investigate the effect of CD62P knockdown on TRALI, mice were treated with anti-CD62P antibody. The results showed that knockdown of CD62P resulted in a decreased lung wet-to-dry weight ratio of mice with TRALI.

CD62P is associated with increases in total protein in the BALF following TRALI. Total protein in the BALF was measured using the Bradford method. The total protein concentration in the BALF in the control group was 0.28±0.04 mg/ml; however, the total protein concentration was increased to 0.57±0.11 mg/ml following induction of TRALI (P<0.05) (Fig. 3). Total protein in the BALF was significantly different between the TRALI + isotype control antibody group and the TRALI + anti-CD62P antibody group, and knockdown of CD62P reduced total protein in the BALF.

CD62P is associated with increases in cytokines in the plasma and BALF following TRALI. The concentration of KC, MIP-2 and IL-6 in the plasma and the BALF was assessed by ELISA. Elevated plasma levels of KC, MIP-2 and IL-6 were observed in the TRALI group compared with those in the control group. The levels of KC, MIP-2 and IL-6 in the plasma following treatment with anti-CD62P Ab were decreased compared with the TRALI + Iso Ab. Values are expressed as the mean ± standard deviation. TRALI, transfusion-related acute lung injury; Iso, isotype; Ab, antibody; KC, keratinocyte-derived chemokine; MIP-2, macrophage-inflammatory protein-2; IL-6, interleukin 6.
TONG et al: ROLE OF CD62P IN TRANSFUSION-ASSOCIATED ACUTE LUNG INJURY

7780

control group (P<0.01) (Fig. 4A). In addition, the concentrations of KC, MIP-2 and IL-6 in the BALF were also increased in the TRALI group compared with those in the control group (P<0.01) (Fig. 5A). However, following treatment with anti-CD62P antibody, the elevation of KC, MIP-2 and IL-6 in the BALF and the plasma of mice with TRALI was markedly attenuated (Figs. 4B and 5B).

CD62P is associated with increases in MPO activity in the lung following TRALI. MPO activity in the lung tissue was assessed using a commercially available ELISA activity assay kit. As shown in Fig. 6, there was a significant increase of MPO activity in the TRALI group in comparison to that in the control group (P<0.01). However, knockdown of CD62P caused a decrease of MPO activity in the lung tissue of mice with TRALI (P<0.01).

CD62P is associated with increases in TATc in the plasma and BALF following TRALI. The concentration of TATc in the BALF and the plasma was determined using an ELISA kit. TATc levels in the plasma were increased in the TRALI group compared with those in the control group (P<0.01) (Fig. 7). Similar results were observed for TATc levels in the BALF (Fig. 8). However, knockdown of CD62P attenuated the increases of TATc in the BALF and the plasma of mice with TRALI, and the levels of TATc were significantly lower in the TRALI + anti-CD62P antibody group compared with those in the TRALI + Iso CD62P antibody group (P<0.01).

Discussion

Certain biomolecules have been demonstrated to be linked with TRAIL, including soluble CD40 ligand, antileukocyte antibodies and lipids (19-21). Clinical studies have indicated that the age of the transfused blood may pre-dispose patients to TRALI (22) and older platelet concentrates are associated with an increased prevalence and severity of transfusion-associated complications (23-25). As CD62P accumulation during storage of A-Plts may be implicated in TRALI (15-18), the present study investigated the precise roles of CD62P in TRALI.

The presence of MHC class I/II antibodies in the transfusion recipient has been indicated to cause TRALI (26-28) and several studies have used animal models of TRALI induced by infusion with antibodies against MHC antigens (14,18,29). In the present study, mice were treated with monoclonal MHC-1 antibody to induce TRALI according to Looney's method (14).

The lung W/D weight ratio is an indicator of pulmonary edema, and the present study showed that the lung W/D weight ratio was increased in the TRALI group compared with that in the control group. Looney et al (18) reported that infusion with MHC-1 antibody caused a decrease in BALF clearance and an increased vascular permeability. The present study found that infusion with MHC-1 antibody resulted in significantly elevated levels of total protein as well as cytokines in the BALF, including KC, MIP-2 and IL-6. These results indicated a decreased BALF clearance and an increased vascular permeability in mice with TRALI. Infusion with MHC-1 antibody not only resulted in pulmonary inflammation, but also in systemic inflammation, as indicated by elevated levels of KC, MIP-2 and IL-6 in the plasma. To further determine the role of CD62P in TRALI, the present study investigated whether in vivo knockdown of CD62P was able to affect the severity of TRALI and its associated effects.

The increases of the lung W/D weight ratio, total protein in the BALF as well as cytokines in the BALF and the plasma were significantly attenuated following anti-CD62P antibody treatment. These results suggested that CD62P was associated with the induction of pulmonary edema, inhibition of BALF clearance, as well as with pulmonary and systemic inflammation in TRALI.
The lung MPO activity, which is an indicator of the total neutrophil content in the lung, was significantly increased in the TRALI group compared with that in the control group. However, anti-CD62P antibody treatment markedly inhibited the MPO activity in the lung. This result suggested that CD62P was associated with neutrophil accumulation in TRALI.

TRALI is the result of endothelial activation, and the endothelium initiates and regulates coagulation (30). It was reported that coagulopathy has important roles in TRALI (31). In the present study, infusion with MHC-1 antibody resulted in increased pulmonary and systemic coagulation, with increased thrombin generation as reflected by the TATc levels. Anti-CD62P antibody treatment attenuated the increase of pulmonary and systemic coagulation in TRALI, as evidenced by decreased TATc levels in the TRALI + anti-CD62P antibody group compared with those in the TRALI group. These results indicated that CD62P was involved in pulmonary and systemic coagulation in TRALI.

In conclusion, the present study established a mouse model of TRALI as evidenced by the presence of pulmonary edema, accompanied by decreased BALF clearance, increased pulmonary and systemic inflammation, elevated lung MPO activity, increased pulmonary as well as systemic coagulation in the MHC-1 antibody infusion group compared with that in the control group. Treatment with anti-CD62P antibody, which silences the interactions involving CD62P, attenuated TRALI in the experimental mice. The present study therefore supported the notion that CD62P is involved in mediating TRALI.

As CD62P accumulates during storage of A-Plts and CD62P is implicated in TRALI, the present study may provide a molecular basis for enhancing the clinical safety and effectiveness of platelet transfusion.

References